Fresh data on protein interactions in Alzheimer’s disease
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease. This work will be presented by Professor Sara Linse of Lund University, Sweden, during the FEBS/EMBO Women in Science Award plenary lecture at FEBS 2019, Krakow, Poland (Sunday 7 July at 2 pm). Her work on the mechanism of amyloid β aggregation and the role of inhibitors demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics will host an extended Q&A session with Professor Linse at their booth (number 7) at 3 pm following her plenary talk. Visitors to the Fluidic Analytics booth will also be able to have an early look at the Fluidity One-W before its official launch later this year. This instrument has the ability to assess on-target protein interactions in solution and in crude biological backgrounds – opening up the possibilities for detailed analysis of proteins in their near-native states and natural environments. The system is easy-to-use, and based on the well-understood relationship between size and diffusion rate, providing researchers with true confidence in the quality and accuracy of their data.
Professor Sara Linse, Department of Biochemistry and Structural Biology, Lund University commented: “During our research into protein amyloid formation, we have used many different techniques for assessing protein interactions – all with different limitations and advantages. With diffusional sizing, we were able to confidently generate accurate and complete in-solution data using amyloid proteins to connect stoichiometry and binding affinities with protein self-assembly. The data we will present at FEBS 2019 could provide key insights for novel therapeutic approaches in Alzheimer’s disease. The Fluidity One-W has contributed significantly to this detailed understanding.”
With applications ranging from neurobiology and cell signalling to drug discovery, the potential impact of diffusional sizing in fundamental scientific research is vast and spans many research areas. Dr Sean Devenish, Head of R&D at Fluidic Analytics explained: “The unique capabilities of the Fluidity One-W position it as the only viable option for analysing difficult-to-study proteins, like amyloid fibrils, in solution. Researchers gain the best insight into what their protein of interest is interacting with, and how, even in complex backgrounds such as crude lysates. The technology is opening up many new avenues of research into protein interactions and expanding the systems that can be studied, and Professor Linse’s recent work is a great example of what’s possible with this new approach to protein analysis.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance